By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Tisagenlecleucel > Tisagenlecleucel Dosage
Miscellaneous antineoplastics
https://themeditary.com/dosage-information/tisagenlecleucel-dosage-10590.html

Tisagenlecleucel Dosage

Drug Detail:Tisagenlecleucel (Tisagenlecleucel [ tis-a-jen-lek-loo-sel ])

Drug Class: Miscellaneous antineoplastics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Acute Lymphoblastic Leukemia

Prior to infusing this drug:
Lymphodepleting chemotherapy: Fludarabine (30 mg/m2 IV daily for 4 days) and cyclophosphamide (500 mg/m2 IV daily for 2 days starting with the first dose of fludarabine); infuse tisagenlecleucel 2 to 14 days after completion of the lymphodepleting chemotherapy.

Tisagenlecleucel:
Up to 25 years:
Body weight 50 kg or less: 0.2 to 5 x 10(6) chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight
Body weight above 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells

Comments:

  • Base the dosage on the patient's weight at the time of leukapheresis.
  • Administer this drug via IV infusion within 30 minutes of thawing at 10 to 20 mL per minute (adjusted as appropriate for smaller children and smaller volumes); the infusion bag volume ranges from 10 to 50 mL.
  • Pre-medicate patients with acetaminophen and diphenhydramine or another H1-antihistamine approximately 30 to 60 minutes prior to infusion of this drug; avoid using corticosteroids at any time except in the case of a life-threatening emergency.

Use: For patients up to 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

Usual Adult Dose for Lymphoma

Prior to infusing this drug:

  • Lymphodepleting chemotherapy: Fludarabine (25 mg/m2 IV daily for 3 days) and cyclophosphamide (250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine)
  • Alternate lymphodepleting chemotherapy: Bendamustine 90 mg/m2 IV daily for 2 days if a patient experienced a previous Grade 4 hemorrhagic cystitis with cyclophosphamide or demonstrates resistance to a previous cyclophosphamide containing regimen; infuse tisagenlecleucel 2 to 11 days after completion of the lymphodepleting chemotherapy.
  • Lymphodepleting chemotherapy may be omitted if a patient's white blood cell (WBC) count is less than or equal to 1 x 10(9)/L within 1 week prior to tisagenlecleucel infusion.

Dose: 0.6 to 6 x 10(8) CAR-positive viable T cells

Use: For adult patients with relapsed or refractory (r/r) large B-cell lymphoma after 2 or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma (NOTE: This drug not indicated for treatment of patients with primary central nervous system lymphoma).

Usual Pediatric Dose for Acute Lymphoblastic Leukemia

Prior to infusing this drug:
Lymphodepleting chemotherapy: Fludarabine (30 mg/m2 IV daily for 4 days) and cyclophosphamide (500 mg/m2 IV daily for 2 days starting with the first dose of fludarabine); infuse tisagenlecleucel 2 to 14 days after completion of the lymphodepleting chemotherapy.

Up to 25 years:

  • Body weight 50 kg or less: 0.2 to 5 x 10(6) chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight
  • Body weight above 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells

Comments:
  • Base the dosage on the patient's weight at the time of leukapheresis.
  • Administer this drug via IV infusion within 30 minutes of thawing at 10 to 20 mL per minute (adjusted as appropriate for smaller children and smaller volumes); the infusion bag volume ranges from 10 to 50 mL.
  • Pre-medicate patients with acetaminophen and diphenhydramine or another H1-antihistamine approximately 30 to 60 minutes prior to infusion of this drug; avoid using corticosteroids at any time except in the case of a life-threatening emergency.

Use: For patients up to 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

MANAGEMENT OF CYTOKINE RELEASE SYNDROME (CRS): Identify CRS based on clinical presentation; evaluate and treat other causes of fever, hypoxia, and hypotension.
If CRS is Suspected, Treat Based on CRS Severity:

  • Prodromal Syndrome (low-grade fever, fatigue, anorexia): Observe in person; exclude infection; administer antibiotics per local guidelines if neutropenic; provide symptomatic support.
  • Overt CRS (one or more of the following: high fever, hypoxia, mild hypotension): Administer antipyretics, oxygen, IV fluids, and/or low-dose vasopressors as needed.

Severe or Life-Threatening CRS (one or more of the following: hemodynamic instability despite IV fluids and vasopressor support; worsening respiratory distress including pulmonary infiltrates, increasing oxygen requirement including high-flow oxygen and/or need for mechanical ventilation; rapid clinical deterioration):
  • Administer high dose or multiple vasopressors, oxygen, mechanical ventilation, and/or other supportive care as needed.
  • Administer tocilizumab: 12 mg/kg IV over 1 hour (if patient weighs less than 30 kg) OR 8 mg/kg IV over 1 hour (maximum dose: 800 mg; if patient weighs 30 kg or greater).

Resistant CRS (no clinical improvement in 12 to 18 hours, or worsening at any time despite prior management):
  • Administer multiple vasopressors, oxygen, mechanical ventilation, and/or other supportive care as needed.
  • Administer methylprednisolone 2 mg/kg as an initial dose, then 2 mg/kg per day until vasopressors and high-flow oxygen are no longer needed, then taper quickly.
  • If no response to steroids within 24 hours, repeat the administration of tocilizumab at 12 mg/kg IV over 1 hour (if patient weighs less than 30 kg) OR 8 mg/kg IV over 1 hour (maximum dose: 800 mg; if patient weighs 30 kg or greater).
  • If no response to the second dose of tocilizumab within 24 hours, consider a third dose of tocilizumab or pursue alternative measures for CRS treatment.

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for tisagenlecleucel. It includes elements to assure safe use. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm.

US BOXED WARNINGS:

  • CYTOKINE RELEASE SYNDROME (CRS): CRS reactions, including fatal reactions, occurred in patients receiving this drug.
  • Do not administer this drug to patients with active infection or inflammatory disorders.
  • Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
  • NEUROLOGICAL TOXICITIES: Neurological toxicities, which may be life-threatening, can occur following therapy with this drug and may occur concurrently with CRS.
  • Monitor for neurological events after treatment with this drug, and provide supportive care as needed.

CONTRAINDICATIONS:
  • None

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:

  • Delay the infusion of this drug if a patient has unresolved serious adverse reactions (e.g., pulmonary reactions, cardiac reactions, hypotension) from preceding chemotherapies, active uncontrolled infection, active graft versus host disease (GVHD), or worsening of leukemia burden following lymphodepleting chemotherapy.
  • Do not wash, spin down, and/or re-suspend this drug in new media prior to infusion.
  • Consult the manufacturer product information for additional administration instructions.

Storage Requirements:
  • This drug is supplied as a frozen suspension in one infusion bag; store the bag in the vapor phase of liquid nitrogen (minus 120 degrees Celsius or less) in a temperature-monitored system.
  • May store this drug at room temperature (20 to 25 degrees Celsius) for up to 30 minutes once it has been thawed.

Preparation/Handling Techniques:
  • Refer to the manufacturer product information for thawing and drug infusion preparation instructions.
  • Employ universal precautions to avoid potential transmission of infectious diseases when handling this drug.

General:
  • Lymphodepleting chemotherapy consists of fludarabine (30 mg/m2 IV daily for 4 days) and cyclophosphamide (500 mg/m2 IV daily for 2 days starting with the first dose of fludarabine).
  • This drug contains human cells genetically modified with a lentivirus, and is prepared from autologous blood collected by leukapheresis.
  • This drug is for autologous and IV use only.

Monitoring:
  • Hepatic: Screening for HBV, HCV, and HIV (before collection of cells for manufacturing)
  • Immunologic: Signs/symptoms of cytokine release syndrome (at least 4 weeks after treatment); immunoglobulin levels (after treatment)
  • Infections/infestations: Signs/symptoms of infection (after treatment)
  • Nervous system: Neurological events (after treatment)
  • Oncologic: Secondary malignancies (life-long)

Patient Advice:
  • Avoid potentially dangerous activities such as driving and operating machinery until you know how this drug affects you.

Frequently asked questions

  • What type of drug is Kymriah (tisagenlecleucel)?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by